CER 209

Drug Profile

CER 209

Alternative Names: CER-209

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cerenis Therapeutics
  • Class Antihyperlipidaemics; Vascular disorder therapies
  • Mechanism of Action P2RY13 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Non-alcoholic steatohepatitis

Most Recent Events

  • 15 Dec 2016 US FDA approves IND application for Non-alcoholic fatty liver disease and Non-alcoholic steato hepatitis and Non-alcoholic fatty liver disease
  • 15 Dec 2016 Cerenis Therapeutics plans a phase I trial for Non-alcoholic fatty liver disease and Non-alcoholic steato-hepatitis
  • 25 Feb 2016 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis released by Cerenis Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top